Historical source coverage

2023, page 2

207 selected records with a cited source date in 2023, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.

Explore 2023 by record type

4 types

January 2023

7 records on this page

Clinical trials · Abaloparatide

ClinicalTrials.gov record NCT03746041

PeptideScanner retained ClinicalTrials.gov record NCT03746041 at 2026-07-30T19:17:35.680Z. Its registry update date was 2023-01-23, and PeptideScanner's reviewed identity mapping was abaloparatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT02967757

PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Bremelanotide

An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.

PubMed lists PMID 36242769 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2022-10-18 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT02440581

PeptideScanner retained ClinicalTrials.gov record NCT02440581 at 2026-07-30T19:17:35.692Z. Its registry update date was 2023-01-05, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Cerebrolysin

ClinicalTrials.gov record NCT04830943

PeptideScanner retained ClinicalTrials.gov record NCT04830943 at 2026-11-16T17:33:14.861Z. Its registry update date was 2023-01-03, and PeptideScanner's reviewed identity mapping was cerebrolysin.

Source: ClinicalTrials.gov ↗

→